Clinical Trial Update: SU5416 in Treating Patients With Advanced, Metastatic, or Recurrent Soft Tissue Sarcomas [Phase 2]

View source ↗

Summary

A Phase 2 study of SU5416 in patients with advanced, metastatic, or recurrent soft tissue sarcomas, including gastrointestinal stromal tumor, has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Stromal Tumor
• Soft Tissue Sarcoma

Drugs mentioned

• SU5416 (semaxanib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Gastrointestinal Stromal Tumor, Sarcoma | Phase 2 | Status: COMPLETED